NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data

Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access 

May 22, 2020

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, this week announced a collaboration for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. The new analysis functionality is built into ROSALIND™ , OnRamp’s cloud-based analysis suite that facilitates data visualization, exploration and collaboration. The companies are releasing these new capabilities through Early Access and immediately offering it to COVID-19 researchers performing critical host response studies on the nCounter platform. 

“ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration amongst researchers,” said Joe Beechem, Chief Scientific Offer and SVP of R&D for NanoString. "This partnership represents a shared vision of accelerating research through making gene expression analysis simple and broadly accessible.” 

ROSALIND is a cloud platform that connects researchers to perform differential expression and pathway exploration in a real-time collaborative environment. The companies are working to make the popular features of NanoString’s nSolver analysis suite available within ROSALIND and are evaluating opportunities for joint development of new analysis solutions. OnRamp Bio recently launched the Coronavirus Community, where participating Scientists are provided with free Scientist access to ROSALIND and the ability to rapidly process datasets and share results with fellow collaborators within the Community. 

The nCounter Platform has been used in over 300 published studies of infectious disease on host immune response, including more than 4 COVID-19 publications. It’s high-plex and wide dynamic range enable studies of pathogen and host gene expression profiles simultaneously with a wide range of sample types. The company announced the availability of a beta panel spike in for COVID-19 research in April and has over 50 customers utilizing the reagents in their research. 

“We are excited to partner with NanoString on advanced tools for gene expression analysis and see opportunities to expand the cloud-based offerings for nCounter data analysis in the future.” said Tim Wesselman, CEO of OnRamp Bio. “Due to the urgent need for COVID-19 researchers to collaborate across geographies, we are making these new analysis and collaboration capabilities available immediately through Early Access.” 

September 2020

Human Paths

Archaeology and genetics are starting to resolve humanity’s origin and spread


Sponsored Product Updates

Western Blot Protein Detection: Enzymatic vs. Fluorescence Methods
Download this article to learn how to pick the best detection technique for your protein research!
Advanced Flow Cytometry Uncovers T Cell Biology
Download this white paper to understand T cell phenotype and function to improve therapeutics research!
Next-Generation Sequencing (NGS) Sample Preparation
Download this white paper to learn the best practices for optimizing sample homogenization in NGS nucleic acid extraction!
Bio-Rad Introduces StarBright Violet 515 Dyefor Flow Cytometry
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 (SBV515) Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry.